A new line of microcarriers for large-scale vaccine and cell therapy manufacturing is now available. The microcarriers can simplify the scale-up of attachment-dependent cells by providing a premeasured, sterile, ready-to-use product for direct transfer into bioreactors. This single-step microcarrier solution can replace several steps traditionally required, which can reduce lab preparation time and enhance manufacturing results. The new microcarriers offer Synthemax II and Enhanced Attachment surface treatment options to help increase cell yield and viability, and are fully compatible with closed systems solutions packaging in customizable batch sizes starting at 10 g.